Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects-Reference-Cited by-同舟云学术

Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects

Published:2017-12-18 Issue:1 Volume:23 Page:1-6
ISSN:1092-8529
Container-title:CNS Spectrums
language:en
Short-container-title:CNS Spectr.

Author:

Stahl Stephen M.

Abstract

Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Clinical Neurology

Reference9 articles.

1. Randomized controlled trial of deutetrabenazine for tardive dyskinesia

2. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia

3. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes

4. Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Oral Vertical Dyskinesia (“Rabbit” Syndrome);Medicina;2024-08-19

2. An Unexpected Phenomenon: A Case of Citalopram-Induced Dyskinesia;Cureus;2024-05-30

3. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system;International Clinical Psychopharmacology;2024-05-11

4. First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133);2024-02-28

5. Tardive Dyskinesia With Chorea-Ballism Improved by Valbenazine: A Case Report;Cureus;2024-02-22